Mark Dixon

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

A Real-World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma.

A Real-World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma.

Journal: EJHaem

Published: January 26, 2026

The perfect storm: human influence on the loss potential of Eunice-like cyclones.

The perfect storm: human influence on the loss potential of Eunice-like cyclones.

Journal: Environmental research letters : ERL [Web site]

Published: June 12, 2025

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.

Journal: Lancet (London, England)

Published: July 23, 2024

Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma.

Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma.

Journal: Blood advances

Published: August 16, 2023

Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform.

Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform.

Journal: Journal of biopharmaceutical statistics

Published: January 13, 2023

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Journal: The New England journal of medicine

Published: December 12, 2022

Design and Evaluation of Interprofessional Training Program for Healthcare Students from Collectivistic Culture.

Design and Evaluation of Interprofessional Training Program for Healthcare Students from Collectivistic Culture.

Journal: Medical science educator

Published: March 11, 2022

The Pillow Project, Infant Choking, and Basic Life Support Training for Prospective Parents: A Low-Cost Intervention for Widespread Application.

The Pillow Project, Infant Choking, and Basic Life Support Training for Prospective Parents: A Low-Cost Intervention for Widespread Application.

Journal: The Journal of perinatal & neonatal nursing

Published: July 24, 2019

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

Journal: The New England journal of medicine

Published: June 06, 2019

Self-extraction with and without a cervical collar: a biomechanical simulation study.

Self-extraction with and without a cervical collar: a biomechanical simulation study.

Journal: Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias

Published: January 19, 2019

Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Journal: Blood

Published: March 23, 2017

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.

Journal: The Lancet. Haematology

Published: January 13, 2017

Showing 1-12 of 17

Last Updated: 09/26/2026